Jamie T. Brogan, MSN, APRN, FNP-BC

Access, Affordability, and Innovation in IBD Care, With Jamie Brogan, NP

 continues to bring both opportunities and challenges, particularly around patient access, individualized care, and navigating an expanding therapeutic pipeline. Despite advances in treatment options, most recently with the US Food and Drug Administration (FDA) approvals of guselkumab (Tremfya) and mirikizumab (Omvoh) in Crohn’s disease, barriers such as insurance restrictions, white bagging, and cost continue to create hurdles for patients.

2025 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) conference

, Jamie Brogan, NP, a nurse practitioner at Northwestern Medicine, discussed positioning medications in Crohn’s disease as more treatment options continue to emerge and new hurdles present unprecedented challenges in patient care.

“I know we all want to live in a world where my medical opinion is what it is and the patient can get the medicine we think is the most appropriate in a timely fashion and stay on it with no barriers. Unfortunately, that's not the world that we live in,” Brogan told 

, emphasizing the importance of taking patient factors like cost, insurance, and potential needle phobias into consideration.

Looking ahead at potential future innovations in the field, Brogan expresses cautious optimism about what may be next, noting that we cannot be entirely sure about how a medicine is going to be used until it is made available. Specifically, she cites agents that she felt looked promising in clinical trials that “did not end up turning out well” as well as agents coming to market with unexpected FDA approvals, like upadacitinib.

“I'm excited to see what ends up getting approved, but until that happens, we have some really strong options and availability now on the market that we're still working our way through in many of our patients,” Brogan said.

She goes on to explain that although IBD does not have a step-by-step algorithm for treatment like other diseases, this presents opportunities to individualize care and consider unique aspects of each patient.

“There are pros and cons to all of the sequencing conversations, but don't be intimidated by it,” Brogan said.

Campbell P. FDA Approves Guselkumab (Tremfya) For Crohn Disease. 

. March 20, 2025. Accessed September 16, 2025. 

https://www.hcplive.com/view/fda-approves-guselkumab-tremfya-for-crohn-disease

Brooks A. FDA Approves Mirikizumab (Omvoh) for Crohn’s Disease. 

. January 15, 2025. Accessed September 16, 2025. 

https://www.hcplive.com/view/fda-approves-mirikizumab-omvoh-for-crohn-disease

Videos

Brogan discusses the various opportunities and challenges that have accompanied recent evolutions in inflammatory bowel disease management.

Shared Decision Making in Crohn’s Disease Management, With Jamie Brogan, NP

 has expanded rapidly, most recently with the US Food and Drug Administration approvals of guselkumab (Tremfya) and mirikizumab (Omvoh), bringing new opportunities for improved outcomes but also greater complexity in clinical decision-making.

With more therapies available, clinicians must balance efficacy, safety, lifestyle considerations, and patient preferences to guide individualized care. At the 

, Jamie Brogan, NP, a nurse practitioner at Northwestern Medicine, discussed positioning medications in Crohn’s disease in a treatment landscape she describes as both exciting and overwhelming.

“Choices increase the length of your discussion talking about different mechanisms of action, different routes of administration, different safety panels, and so this conversation with our patients in shared decision making gets longer and more complex, and sometimes increased options can increase confusion for patients,” Brogan told 

. “I appreciate how exciting this is, but I also appreciate that this can complicate the conversation and extend it”

To streamline these discussions, Brogan emphasizes the value of decision aids like one-page comparison tools or online resources that help patients clearly weigh their options. In her view, patients who are engaged in understanding their disease and treatment choices often achieve better long-term outcomes.

While she says many of her patients have already begun advanced therapy before she sees them, Brogan says for those at the start, she sees it as an opportunity to both educate and reassure. These discussions are especially critical given Crohn’s disease often affects young adults facing lifelong treatment, underscoring the importance of aligning therapy with individual goals—such as study abroad, pregnancy planning, or career milestones—while balancing safety, efficacy, and lifestyle considerations.

“Healing is a priority, but the whole patient is really the priority, so bringing these parts of the human experience into the conversation is really important,” Brogan explained.

When therapies fail, she emphasizes the importance of carefully analyzing why. Factors such as coexisting autoimmune conditions, adverse effects like psoriasis from TNF inhibitors, comorbidities such as multiple sclerosis or heart failure, and disease severity all shape the next steps in treatment selection.

Ultimately, Brogan stresses that positioning medications in Crohn’s disease requires not only evidence-based knowledge but also a holistic, patient-centered approach that integrates the science of IBD management with the realities of patients’ lives.

. March 20, 2025. Accessed September 10, 2025. 

. January 15, 2025. Accessed September 10, 2025. 

Brogan explains how to navigate the complexities of the Crohn’s disease treatment landscape and why patients need to be included in the decision making process.

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.

Resources for Patients and Providers on Adalimumab Biosimilars

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The conversation delves into various educational resources utilized both by healthcare providers and patients regarding ddalimumab biosimilars. Providers emphasize the importance of authoritative sources such as the FDA and professional societies like the American College of Rheumatology for accurate information on interchangeability and biosimilars.

While some providers note a lack of comprehensive resources, they highlight the American Academy of Dermatology and New Zealand DermNet as useful references. Patient education materials from organizations like the Crohn's and Colitis Foundation are also recommended.

Providers stress the need for proactive patient engagement and filtering information from reliable sources, discouraging reliance on social media or blogs for medical advice. To ensure patient understanding, nurses play a crucial role in creating educational tools and facilitating communication, including preemptive notifications about changes in medication availability.

Overall, the discussion underscores the importance of ongoing education and communication between healthcare providers and patients to optimize treatment outcomes with Adalimumab biosimilars.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Providers in inflammatory diseases discuss the instrumental role nurses and support staff play in educating patients on adalimumab biosimilars.

The Role of Nurses and Support Personal in Educating Patient on Adalimumab Biosimilars

The conversation centers on the crucial role of nurses and support staff in educating patients and ensuring optimal outcomes with adalimumab biosimilars. Nurses are highlighted as key educators who interact closely with patients, providing training on device usage and addressing any issues that arise. Support staff, including specialty pharmacists and biologics coordinators, also play essential roles in managing patient concerns, such as delays in medication delivery or copay assistance.

Providers emphasize the importance of patient education from the outset, including information on risks, side effects, and access to copay assistance programs. Proactive patient engagement is encouraged, with patients urged to communicate any issues promptly to facilitate timely resolution.

Collaboration between healthcare providers, pharmaceutical companies, and support staff is crucial in navigating the complexities of insurance coverage and product availability. Open communication and ongoing education ensure that patients receive comprehensive support throughout their treatment journey, despite potential changes in coverage and policies over time.

Jamie T. Brogan, MSN, APRN, FNP-BC

Articles